EAST NORRITON, Pa., Feb. 27 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that it has appointed Jeff Randall to its Board of Directors. Mr. Randall brings more than 25 years experience as a senior- level executive, CFO and CEO at public and private companies to Tengion, including expertise in the healthcare, device manufacturing and electronics industries.
"We are pleased to welcome Jeff to the Tengion Board of Directors," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "His expertise in developing the financial infrastructure for biotech companies will be a valuable addition to our Board and we look forward to working with him."
Mr. Randall's career has included serving as CFO at seven companies, three of which then appointed him to the post of CEO. Now a financial consultant, he most previously held management team positions at Eximias Pharmaceutical Corporation and i-STAT Corporation and has extensive experience working with and serving on Boards of Directors. Mr. Randall received his B.S. from The Pennsylvania State University, his M.B.A. from Northeastern University and served in the U.S. Air Force.
"Tengion's technology and the strength of its management team and Board of Directors made this an exciting opportunity," said Mr. Randall. "I am looking forward to working with the company and my fellow members of the Board to realize Tengion's potential and help the company achieve its corporate goals."
Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure - rather than treat - organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.
|SOURCE Tengion Inc.|
Copyright©2008 PR Newswire.
All rights reserved